Option Deal Structure Works For Myriad As It Moves To Buy Crescendo
This article was originally published in The Gray Sheet
Having watched Crescendo Bioscience gain a foothold in the market for inflammatory and autoimmune diagnostics, Myriad Genetics is now moving to acquire the company – a right it obtained via a novel strategic investment agreement in 2011.
You may also be interested in...
Given Imaging, soon to be part of Covidien, gained clearance for PillCam Colon capsule endoscopy device. FDA approves its first continuous glucose monitoring system for kids. Congress makes progress in the sustainable growth rate formula bill. More news.
Veracyte has launched a complex molecular diagnostic test in thyroid in record time and with impressive capital efficiency. It could be a model for high-value diagnostics, especially if the company can successfully adopt its approach in a broader market.
Oncology oriented Myriad Genetics is investing $25 million in Crescendo Bioscience, a developer of molecular diagnostics for inflammatory disorders. The deal aims at more than a financial return: it includes a 3-year option to acquire Crescendo. That would strengthen Myriad's protein-based test development capabilities. Adding Crescendo to the fold would be consistent with Myriad's focus on service-based offerings -- often a predicate for success in commercializing high-value diagnostics.